Abstract 201P
Background
Immunotherapy provided a new treatment alternative for cancer, but many patients still do not respond due to tumor-induced immunological dysfunction. Aerobic exercise training (AET) has emerged as a strategy to reduce cancer mortality and improve immune response, however the mechanisms explaining AET benefits immune system on cancer remain unclear. Thus, our aim was to evaluate whether AET could positively modify the tumor microenvironment, favoring infiltration and cytotoxicity of “antitumor” lymphocytes by regulating their mitochondrial content and function.
Methods
Balb/c male mice were submitted to 4 weeks of AET (60% of maximal capacity, 5 days/week, 1 h/day) before inoculation (s.c.,1x106 CT26 colon carcinoma cells). CT26 TR continued AET after inoculation and all groups were euthanized 9 days post tumor cells inoculation for further analysis. Tumor volume was measured daily. Experimental groups were divided into control (healthy sedentary mice), CT26 SED (sedentary tumor-bearing mice) and CT26 TR (trained tumor-bearing mice). Tumor-infiltrated T lymphocytes and mitochondrial density were measured by flow cytometry. Tumor hypoxia was measured by Hypoxyprobe Kit. Mitochondrial morphology was evaluated by electron microscopy and ATP production by an ATP Determination Kit. Statistical analysis: Anova One-way, Duncan post hoc, p<0.05. Ethical approval: CEUA EEFE-USP 2017/02.
Results
CT26 TR mice showed attenuated tumor progression when compared with CT26 SED group, with significant smaller tumor volume and mass. AET significantly reduced tumor hypoxic area compared to CT26 SED group. AET significantly increased the total amount of activated and effector memory CD8+ T cells, and effector memory CD4+ T cells in CT26 TR when compared to CT26 SED in the tumor. Additionally, increased function of T CD8+ cells in CT26 TR was followed by a higher mitochondrial number/cell and function (ATP production) in this cells compared with CT26 SED group.
Conclusions
AET increases tumor-infiltrated cytotoxic/effector CD8+ T cells and improves their mitochondrial content and function. These data suggest that AET can attenuate tumor growth by modulation of tumor-infiltrated lymphocytes number and profile.
Legal entity responsible for the study
The authors.
Funding
São Paulo Research Foundation (FAPESP, 11800-4/2021, 2015/22814-5, and 2017/13133-0).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
136P - Circadian rhythm positioned chronomodulated-SBRT with Cancer associated fibroblast elimination theranostic treatment to harmonize resistant TFG-Beta stromal microenvironment in conjunction with PDL-1 based immunotherapy in disseminated cancers-Concept randomised study.
Presenter: G Lohith
Session: Poster Display
137P - First-in-human results from a Phase I dose-escalation study of VSV-GP (BI 1831169) in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster Display
138P - Generation of frameshift mutated TGF_R2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF
Presenter: Else Inderberg
Session: Poster Display
139P - Safety and clinical activity of a novel anti-CCR8 antibody (LM-108) as a single agent or in combination with pembrolizumab in patients with advanced solid tumors: Results of phase 1 study
Presenter: Alexander Starodub
Session: Poster Display
140P - Eliciting mAbs targeting MHC-bound peptides with a novel antibody discovery platform
Presenter: Elli Sandberg
Session: Poster Display
141P - An IgE antibody targeting the melanoma-associated Chondroitin Sulfate Proteoglycan 4
Presenter: Lais Cristina Palhares
Session: Poster Display
142P - Identifying novel immunotherapy targets using machine learning and ex vivo validation
Presenter: Marcellus Augustine
Session: Poster Display
143P - Advancing Cancer Immunotherapy via HLA-G Pathway Modulation with UCB4594
Presenter: Ann WHITE
Session: Poster Display
144P - Discovery of CBO421, a first-in-class Drug Fc-Conjugate (DFC), targeting CD73 in Cancer
Presenter: Simon Döhrmann
Session: Poster Display
145P - An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles
Presenter: ZONG SEAN JUO
Session: Poster Display